Khurram Jamil
Known title: Chief Medical OfficerCIK: 0002032345
Associated companies
Transaction History
| GALT | ▼ Sell | Open Market | 16,250 | $83K | 7/14/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 16,250 | $49K | 7/14/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 47,467 | $119K | 6/29/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 47,467 | $239K | 6/29/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 2,037 | $10K | 6/26/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 2,037 | $4K | 6/26/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 2,533 | $6K | 6/26/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 2,533 | $13K | 6/26/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 7,557 | $24K | 6/23/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 7,557 | $9K | 6/23/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 568 | $699 | 5/26/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 568 | $2K | 5/26/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 21,446 | $78K | 1/6/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 25,499 | $99K | 1/5/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 13,055 | $55K | 1/2/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 60,000 | $0 | 1/2/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 8,125 | $33K | 12/31/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 8,125 | $10K | 12/31/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 8,500 | $60K | 12/17/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 4,479 | $32K | 12/17/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 6,463 | $14K | 12/17/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 8,500 | $21K | 12/17/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 6,463 | $45K | 12/17/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 41,500 | $91K | 11/13/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 41,500 | $227K | 11/13/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 41,500 | $104K | 11/13/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 41,500 | $227K | 11/13/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 16,250 | $89K | 11/13/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 21,867 | $120K | 11/13/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 16,250 | $20K | 11/13/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 40,000 | $0 | 12/23/2024 | View on chart |
| GALT | ▼ Sell | Open Market | 13,654 | $12K | 12/23/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.